Friedemann Paul group

AG Paul

Klinische Neuroimmunologie

Profil

Unser Fokus liegt auf der Verbesserung der diagnostischen und therapeutischen Möglichkeiten bei neuroimmunologischen Erkrankungen, insbesondere bei der Multiplen Sklerose.

Wir arbeiten dabei mit einem translationalen Ansatz; das bedeutet, dass wir versuchen, neue Entwicklungen und Erkenntnisse aus der Forschung unmittelbar in die klinische Arbeit zu überführen.

Die AG Klinische Neuroimmunologie ist eine von vier Arbeitsgruppen am NeuroCure klinischen Forschungszentrum (NCRC).

Hier finden Sie die Pressemitteilung zu unseren neuesten Ergebnissen.

Veröffentlichungen

Nachrichten

Kooperationspartner

Hier finden Sie ausgewählte Kooperationspartner:
  • Klinik für Neurologie, Charité - Universitätsmedizin Berlin
  • Experimental and Clinical Research Center Berlin, Charité – Universitätsmedizin Berlin und Max-Delbrück Zentrum für Molekulare Medizin (Prof. Dr. T. Niendorf, Dr. C. Infante)
  • Bernstein Center for Computational Neuroscience, Berlin (Prof. J. Haynes)
  • Klinik und Poliklinik für Neurologie, Universitätsklinikum Münster (Prof. Dr. E. Ringelstein, Dr. I. Kleffner)
  • Klinik und Poliklinik für Neurologie, Universitätsklinikum Hamburg Eppendorf (Prof. Dr. C. Heesen)
  • Klinik für Neurologie, Heinrich-Heine Universität Düsseldorf (Prof. Dr. O. Aktas, Dr. M. Ringelstein, Prof. Dr. H.-P. Hartung)
  • Neurologische Klinik, Ruprecht-Karls-Universität, Heidelberg (Dr. S. Jarius, Prof. B. Wildemann)
  • Klinik und Poliklinik für Neurologie der Universität Ulm (Prof. H. Tumani, Prof. v. Arnim)
  • Klinik und Poliklinik für Neurologie, Neurologische Universitätsklinik, Klinikum Carl Gustav Carus, Dresden (PD Dr. T. Ziemssen)
  • Zentrum für Muskel- und Knochenforschung, Charité – Universitätsmedizin Berlin (Prof. Dr. D. Felsenberg, Dr. G. Armbrecht)
  • Neurology Department, Mayo Clinic, USA (Prof. B. Weinshenker)
  • Department of Neurosciences, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona Spanien (Prof. Dr. P. Villoslada)
  • Department of Neurobiology, Weizman Institute of Science, Rehovot, Israel (Prof. A. Zangen)
  • Technion, Israel Institute of Technology, Haifa, Israel (Prof. Y. Moudim, Dr. S. Mandel)
  • Gfnmediber GmbH Berlin (A. Brandt)
  • Heidelberg Engineering GmbH, Heidelberg
  • Brainsway, Jerusalem, Israel 
  • Abteilung Neuropathologie, Universitätsmedizin Göttingen (Prof. Dr. W. Brück)
  • Klinik für Neurologie, UniversitätsSpital Zürich (Dr. S. Schippling)
  • Beuth Hochschule für Technik Berlin (Prof. Dr. H. Dietze)
  • Kooperation zwischen BIH und Startupbootcamp

Klinische Studien

 

Research Outpatient Clinic

 

BERLimmun

Berlin Registry of Neuroimmunological Entities (BERLimmun) - a monocentric prospective observational study on the long-term course of neuroimmunological diseases.

Sponsor: IIT

Recruitment: yes

Local PI: PD Dr. Tanja Schmitz-Hübsch

Study Number: German Clinical Trial Register DRKS00026761

 

Akute ON

Acute Optic Neuritis Study (AON-S), a monocentric, prospective observational study on symptomatology, diagnosis, therapy and prognosis of acute optic neuritis.

Sponsor: IIT

Recruitment: yes

Local PI: Dr. Susanna Asseyer/Prof. Dr. Friedemann Paul

Study Number: NCT05605951

 

COGEMS II

Neural mechanisms of mental and emotional processes in multiple sclerosis and their relevance to disease severity.

Sponsor: IIT

Recruitment: yes

Local PI: PD Dr. Martin Weygandt

 

EFC16645 Hercules BTkI phase iii

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES).

Sponsor: Sanofi

Recruitment: Screening closure 29.11.2022

Local PI: Prof. Dr. Friedemann Paul

Study Number: EudraCT 2020-000647-30 

 

EFC16035 PERSEUS BTkI phase iii

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS).

Sponsor: Sanofi

Recruitment: yes

Local PI: Prof. Dr. Friedemann Paul

Study Number: EudraCT 2020-000645-14 

 

GenSeMS Project

Sponsor: IIT

Recruitment: yes

Local PI: Prof. Dr. Stefan Gold

 

HOPE-MS

Clinical validity of confirmed disease progression defined by marker-less home-based assessment of motor function in multiple sclerosis (HOPE-MS).

Sponsor: IIT (Celgene)

Recruitment: yes

Local PI: PD. Dr. Tanja Schmitz-Hübsch

 

Kyrios phase IV

Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS).

Sponsor: Novartis

Recruitment: closed

Local PI: Prof. Dr. Friedemann Paul

 

WN43194 Satralizumab phase iii (Meteoroid)

A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab as monotherapy or in addition to baseline therapy in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

Sponsor: Roche

Recruitment: yes

Local PI: PD. Dr. Tanja Schmitz-Hübsch

Study Number: NCT05271409

 

Study MOG001 (Parexel 247511) phase iii (CosMOG)

A Randomized, double-blind, Placebo-controlled, multicenter Phase 3 pivotal study to evaluate the efficacy and safety of rozanolixizumab to treat adult patients with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD).

Sponsor: UCB

Recruitment: yes

Local PI: Prof. Dr. Friedemann Paul

Study number: NCT05063162

 

Motosense

Sensitivity of quantitative motor performance measures in multiple sclerosis – a prospective cohort study over two years using Microsoft Kinect.

Sponsor: IIT

Recruitment: closed

Local PI: Prof. Dr. Friedemann Paul

 

MSIM 7T

7 Tesla MRI in patients with multiple sclerosis and other neuroimmunological disorders.

Sponsor: IIT

Local PI: Prof. Dr. Friedemann Paul

 

PREPARE phase II

Prevention of paclitaxel-related neurologic adverse events with lithium - a randomized, double-blind, placebo-controlled, exploratory proof-of-concept phase II clinical trial for the prevention of chemotherapy-induced neurotoxicity.

Sponsor: IIT

Recruitment: yes

Local PI: Prof. Dr. Mathias Endres

 

QMS (MR Elastographie BCAN)

MR elastography in patients with multiple sclerosis.

Sponsor: IIT

Local PI: Prof. Dr. Ingolf Sack

 

RDoC

Sponsor: IIT

Recruitment: yes

Local PI: Prof. Dr. Stefan Gold/Prof. Dr. Isabel Dziobek

 

PRECOMS Schwangersch. und MS

Database on family planning and pregnancies in multiple sclerosis and Neuromyelitis optica spectrum disease (PreCoMS).

Sponsor: IIT

Local PI: Prof. Dr. Friedemann Paul

 

TempiMS

Specified laboratory investigations in Portugal.

Sponsor: IIT

Recruitment: yes

Local PI: Prof. Dr. Friedemann Paul

 

TregNMO

Regulatory T cells in Neuromyelitis optica.

Sponsor: IIT

Recruitment: yes

Local PI: Dr. Maria Hastermann

 

Valkinect (incl Ataxie)

Determining the accuracy, reliability, validity, and responsiveness of video-operceptive motion analysis with Microsoft Kinect - VALKINECT.

Sponsor: IIT

Recruitment: yes

Local PI: Prof. Dr. Friedemann Paul

 

 

Neuroimmunological Outpatient Clinic (Hochschulambulanz)

 

CFS-CARE

Care Model for Patients with Chronic Fatigue Syndrome (ME/CFS).

Sponsor: IIT

Recruitment: yes

Local PI: Prof. Dr. Carmen Scheibenbogen

 

DMSG MS-Register

Patient registry of the German Multiple Sclerosis Society, Federal Association (DMSG) within the MS Research and Project Development GmbH (MSFP), DMSG MS-Register.

Sponsor: DMSG

Recruitment: yes

Local PI: Prof. Dr. Friedemann Paul

 

PreCoMS

Family planning and pregnancies in multiple sclerosis (PreCoMS)

Sponsor: IIT

Recruitment: yes

Local PI: Dr. Nadja Siebert

Study Number: NCT05010902

 

POST COVID Beobachtungsstudie (PA-COVID-19)

Analysis of the Pathophysiology and Pathology of Corona Virus Disease 2019 (Pa-COVID-19).

Sponsor: IIT

Recruitment: yes

Local PI: Prof. Carmen Scheibenbogen / Dr. Judith Bellmann-Strobl

 

PA-COVID-19-Unterstudie

Dynamic vascular analysis of the retina in the Pa-COVID-19 study.

Sponsor: IIT

Recruitment: yes

Local PI: Prof. Dr. Friedemann Paul

 

VERI-LONG

A study to investigate improvement in physical function in SF-36 with Vericiguat compared with Placebo in participants aged 18 to 50 years with post-COVID-19 syndrome (PCS and PCS/CFS).

Sponsor: IIT (Bayer)

Recruitment: yes

Local PI: Dr. Judith Bellmann-Strobl

Study Number: EudraCT 2021-005494-11   NCT05697640

 

 

Friedemann Paul
Prof. Dr. Friedemann Paul
Gruppenleiter
Kontakt

NeuroCure Clinical Research Center
Charité Campus Mitte

Tel:  +49 (0)30 450 539 705
Fax: +49 (0)30 450 539 915
friedemann.paul@charite.de

 

 

Experimental and Clinical Research Center
Lindenberger Weg 80
13125 Berlin